Joseph Snyder is the Managing Partner of the firm's Walnut Creek office. He focuses his practice on patent prosecution and counseling, emphasizing patent drafting, patent procurement, client counseling and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies' commercial potential, enforcement of patent rights and defense of infringement allegations. Dr. Snyder represents U.S. and foreign companies, such as pharmaceutical companies, diagnostic laboratories, universities and start-ups in all areas of intellectual property counseling and protection.
He conducts and performs due diligence investigations in connection with commercial transactions, such as mergers, acquisitions and the establishment of strategic business alliances. These investigations involve intellectual property including patents, technology licenses, acquisition agreements and asset purchase agreements. Dr. Snyder advises on the creation of start-ups and their patent portfolio development. He coordinates and negotiates the transfer and licensing of intellectual property as it relates to office of technology transfer agreements, collaborative/sponsored research agreements and other transfer agreements.
His technology experience includes small molecules, pharmaceutical formulations, drug delivery technologies, medical diagnostics, nucleic acid assays, nucleic acid sequencing technologies, dyes and clean technology, such as fuel cells.
Before joining the firm, Dr. Snyder worked as a patent attorney for Zeneca Ag Products in the areas of patent drafting, patent prosecution and patent validity opinions.
Prior to joining the legal profession, he was a senior scientist in their analytical department doing organic structural analysis using NMR and mass spectrometry.
Dr. Snyder was recognized as a 2014, 2015, 2016 and 2017 Northern California "Super Lawyer" in the area of Intellectual Property by Super Lawyers magazine.
Represented Prometheus Laboratories, Inc. owner of an Orange Book listed branded drug, Lotronex (alosetron hydrochloride), indicated for women with severe Irritable Bowel Syndrome. Prometheus Labs bought the franchise from GSK several years ago, however US Patent No. 6,284,770 drawn to a method for treatment was not listed in the Orange Book. A reexamination strategy was devised to ensure patentability of the claims that covered the indication. After an initial PTO action denying the reexamination request, a petition was filed citing further relevant facts. Thereafter, the petition was granted. After successful prosecution of amended claims, a reexamination certificate issued providing valid patent coverage for Lotronex. The reexamined patent is now listed in the Orange Book.
Insights View All
University of San Francisco School of Law, J.D. (1995)
University of Notre Dame, Ph.D., Chemistry (1987)
University of Akron, M.S., Chemistry (1983)
Xavier University, B.S., Chemistry (1980)
U.S. Patent and Trademark Office (1995)
Supreme Court of California (1995)
Supreme Court of the United States (2011)
International Association for the Protection of Intellectual Property, Standing Committee on Pharma and Biotechnology for the US National Group
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.